enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Drop in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 4,663 shares, a drop of 90.4% from the August 15th total of 48,573 shares. Based on an average daily trading volume, of 13,212 shares, the days-to-cover ratio is presently 0.4 days.

enGene Price Performance

Shares of NASDAQ:ENGNW remained flat at $0.23 during midday trading on Thursday. The business has a 50-day simple moving average of $0.29 and a two-hundred day simple moving average of $1.08. enGene has a 1 year low of $0.11 and a 1 year high of $4.20.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.